Clinical trial ETOP 12-17 ALERT-lung
A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC (ETOP 12-17 ALERT-lung)
Cancers | |
---|---|
Organ | NSCLC |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | IBCSG |
EudraCT Identifier | 2017-002063-17 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03445000 |
Inclusion criteria | At least one prior platinum-based systemic regimen/ RET |
Last update |